Bovie Medical's J-Plasma an All-Star Product

Stephen L Kanaval  |

Bovie Medical Corporation (BVX) has a new J-Plasma product line that is getting excellent reviews. The laparoscopic hand–piece is used for surgical tissue cutting, and the signature cut is made by passing an inert gas over a unique blade and forming it into a plasma stream, hence J-Plasma.

J-Plasma works at far lower temperatures than traditional CO2 lasers, resulting in less damage to surrounding tissue. Surgeons treating women with endometriosis, for example, can now remove diseased tissue on the fallopian tubes without fear of damaging these delicate structures. This can improve the likelihood of more effective treatment, potentially reducing the need for repeat procedures. This is an all-star product that has applications for numerous delicate tissue procedures, and, not to mention, it was recognized as Innovation of the Year by The Society of Laparoscopic Surgeons. To get an idea of how exciting this product is, look at this graph from a case study below:

The J-Plasma is more practical, cuts with greater precision, and is cheaper. Currently, the company will see the J-Plasma used in mostly in GYN procedures, but I think as this year goes by you will see the cutting tool start to be used in other specialty areas. Bovie Medical has really worked to build its medical advisory board to access these areas and get approvals easier. Here is what CEO Robert Gershon said on conference call this year:

Last quarter, I discussed the formation of a medical advisory board to assist us in determining those specific procedures in other surgical specialties for which J-Plasma is well suited for broad-based adoption. Our first member, Dr. Vip Patel, a world renowned urologist and leader in robotic surgery believes that J-Plasma has the potential to significantly benefit patients undergoing surgery for prostate cancer.

One of the strategic initiatives I mentioned earlier is the progress we have made in building out the Medical Advisory Board. The two new surgeon members we announced in our third quarter earnings release are at the top of their fields, Dr. Husam Balkhy, is director of robotic and minimally invasive and cardiac surgery at the University of Chicago Medicine; and Dr. Robert Cerfolio, is Professor of surgery and section chief of thoracic surgery at the University of Alabama Hospital.

Bovie clearly believes in their product and have put together an experienced team to find good use for it. In addition, Bovie now has a fully trained sales team out there promoting the J-Plasma, Gershon himself is also deft at his craft.

Gershon has over 25 years in the healthcare sector and served as Vice President of Sales and Marketing at Henry Schein ($1.4 billion shared P&L for medical division/$115 million full P&L for dialysis division). It is clear that Bovie and Gershon are positioning themselves to make serious headway with the J-Plasma in 2016.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
BVX Bovie Medical Corporation 5.69 -0.36 -5.95 184,947

Comments

Emerging Growth

MGX Minerals Inc.

MGX Minerals is a diversified Canadian mining company listed on the Canadian Securities Exchange. MGX is engaged in the acquisition and development of industrial mineral deposits in western Canada that…